BAM
ELDN icon

Byrne Asset Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Byrne Asset Management’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4 Hold
1
– – ﹤0.01% 587
2026
Q1 		$3 Hold
1
– – ﹤0.01% 565
2025
Q4 		$2 Buy
+1
New +$2 ﹤0.01% 559

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Byrne Asset Management's ELDN Position: Q2 2026 in Review

Byrne Asset Management held its Eledon Pharmaceuticals (ELDN) position steady in Q2 2026 at 1 share worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #587.

Byrne Asset Management first reported a position in ELDN in Q4 2025 and has held it in 3 quarters since. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Byrne Asset Management held 1 share of Eledon Pharmaceuticals worth $4 as of Q2 2026.
  • Byrne Asset Management left its Eledon Pharmaceuticals share count unchanged in Q2 2026.
  • Eledon Pharmaceuticals made up ﹤0.01% of Byrne Asset Management's portfolio in Q2 2026, its #587 holding.
  • Byrne Asset Management first reported a position in Eledon Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Byrne Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.